Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Lane, Jane; Martin, Tracey Amanda; Watkins, Gareth; Mansel, Robert Edward; Jiang, Wen Guo (2008)
Publisher: Spandidos Publications
Languages: English
Types: Article
Subjects: RC0254
The role and expression of ROCKI and ROCKII in human breast cancer was investigated and the effect on clinical outcome assessed. ROCK knockdown cells (MDA-MB-231ΔROCKI and MDA-MB-231ΔROCKII were tested for their in vitro invasiveness, motility and in vivo tumour growth. Samples of fresh frozen breast tumour tissue (n=113) and normal background tissue (n=30) were processed for immunohistochemical and quantitative RT-PCR analyses. MDA-MB-231ΔROCKI and MDA-MB-231ΔROCKII cells showed significantly decreased invasiveness compared with control cells (mean ± SEM 4.33±0.84 MDA-MB-231ΔROCKI vs. 18.4±1.4 control, p<0.001; 6.8±1.2 MDA-MB-231ΔROCKII vs. 18.4±1.4 control, p<0.001). Similarly, both exhibited reduced motility compared with control cells (p<0.001) and lost their response to HGF. Importantly, no significant difference existed between knockdown and control cells in in vivo tumour growth. ROCKI was significantly higher in human mammary tumours than normal background tissue (2.9±1.1 vs. 0.29±0.13, p=0.023), although expression of ROCKII was fairly consistent in both (2050±646 vs. 2303±2079). ROCKI expression was greater in patients who died from breast cancer than in patients who remained disease free (11.6±7.1 vs. 1.95±0.95). Higher levels of ROCKI were associated with increased grade (0.95±0.73 grade-1; 2.11±1.72 grade-2; and 4.06±1.99 grade-3). Levels of ROCKI, but not ROCKII, were significantly correlated with overall survival of patients (p=0.004, Univariate analysis, median follow-up 120 month). These results show that ROCKI and possibly ROCKII are key factors in regulation of motility/invasion of breast cancer cells. This, together with significant correlation between ROCKI and poor outcome in clinical breast cancer, indicates that it is a potential target in human breast cancer.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Hall A: Rho GTPases and the actin cytoskeleton. Science 11: 2295-2322, 1998.
    • 2. Ridley AJ: Rho GTPases and cell migration. J Cell Sci 114: 2713-2722, 2001.
    • 3. Takaishi K, Sasaki T, Kotani H, Nishioka H and Takai Y: Regulation of cell-cell adhesion by rac and rho small G proteins in MDCK cells. J Cell Biol 137: 1421-1431, 1997.
    • 4. Jaffe AB and Hall A: Rho GTPases in transformation and metastasis. Adv Cancer Res 84: 57-80, 2002.
    • 5. Del Peso L, Hernandez-Alcoceba R, Embade N, Carnero A, Esteve P, Paje C and Lacal JC: Rho proteins induce metastatic properties in vivo. Oncogene 15: 3047-3057, 1997.
    • 6. Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y and Oshima H: Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 9: 2632-2641, 2003.
    • 7. Fritz G, Just I and Kaina B: Rho GTPase overexpressed in human tumours. Int J Cancer 81: 682-687, 1999.
    • 8. Jiang WG, Watkins G, Lane J, Cunnick GH, Douglas-Jones A, Mokbel K and Mansel RE: Prognostic value of Rho GTPases and Rho guanine nucleotide dissociation inhibitors (GDI's) in human breast cancers. Clin Cancer Res 17: 6432-6440, 2003.
    • 9. Bishop AL and Hall A: Rho GTPases and their effector proteins: Biochem J 348: 241-255, 2000.
    • 10. Wang DS, Dou KF, Li KZ and Song ZS: Enhancement of migration and invasion of hepatoma cells via a Rho GTPase signaling pathway. World J Gastroenterol 10: 299-302, 2004.
    • 11. Nishimura Y, Itoh K, Yoshioka K, Tokuda K and Himeno M: Overexpression of ROCK in human breast cancer cells: evidence that ROCK activity mediates intracellular membrane traffic of lysosomes. Pathol Oncol Res 9: 83-95, 2003.
    • 12. Ishizaki T, Naito M, Fujisawa K, Maekawa M, Watanabe N, Saito Y and Narumiya S: p160ROCK, a Rho-associated coiledcoil forming protein kinase, works downstream of Rho and induces focal adhesions. FEBS Lett 404: 118-124, 1997.
    • 13. Riento K and Ridley AJ: ROCKS: Multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 4: 446-456, 2003.
    • 14. Sahai E, Garcia-Medina R, Pouysségur J and Vial E: Smurf1 regulates tumor cell plasticity and motility through degradation of Rho A leading to localized inhibition of contractility. J Cell Biol 176: 35-42, 2007.
    • 15. Torka R, Thuma F, Herzog V and Kirfel G: ROCK signaling mediates the adoption of different modes of migration and invasion in human mammary epithelial tumor cells. Exp Cell Res 312: 3857-3871, 2006.
    • 16. Nakajima M, Hayashi K, Egi Y, Katayama K, Amano Y, Uehata M, Ohtsuki M, Fujii A, Oshita K, Kataoka H, Chiba K, Goto N and Kondo T: Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma. Cancer Chemother Pharmacol 52: 319-324, 2003.
    • 17. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T and Narumiya S: An essential part for Rho-associated kinase in the transcellular invasion of tumour cells. Nat Med 5: 221-225, 1999.
    • 18. Imamura F, Mukai M, Ayaki M and Akedo H: Y-27632, an inhibitor of Rho-associated protein kinase, suppresses tumour cell invasion via regulation of focal adhesion and focal adhesion kinase. Jpn J Cancer Res 91: 811-816, 2000.
    • 19. Croft DR, Sahai E, Mavria G, Li S, Tsai J, Lee WM, Marshall CJ and Olson MF: Conditional ROCK activation in vivo induces tumor cell dissemination and angiogenesis. Cancer Res 64: 8994-9001, 2004.
    • 20. Vishnubhotla R, Sun S, Huq J, Bulic M, Ramesh A, Guzman G, Cho M and Glover SC: ROCK-II mediates colon cancer invasion via regulation of MMP-2 and MMP-13 at the site of inva-dopodia as revealed by multiphoton imaging. Lab Invest 87: 1149-1158, 2007.
    • 21. Kamai T, Arai K, Sumi S, Tsujii T, Honda M, Yamanishi T and Yoshida K: The rho-rho kinase pathway is involved in the progression of testicular germ cell tumour. BJU Int 89: 449-453, 2002.
    • 22. Kamai T, Yamanishi T, Shirataki H, Takagi K, Asami H, Ito Y, Yoshida K: Overexpression of RhoA, Rac1 and Cdc42 GTPases is associated with progression in testicular cancer. Clin Cancer Res 10: 4799-4805, 2004.
    • 23. Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD, Mokbel K and Mansel RE: Targeting matrilysin and its impact on tumour growth in vivo: the potential implications in breast cancer therapy. Clin Cancer Res 11: 6012-6019, 2005.
    • 24. Martin TA, Parr C, Davies G, Watkins G, Lane J, Matsumoto K, Nakamura T, Mansel RE and Jiang WG: Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis 24: 1317-1323, 2003.
    • 25. Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K and Narumiya S: ROCK-I and ROCK-II, two isoforms of Rhoassociated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 392: 189-193, 1996.
    • 26. Suyama E, Kawasaki H, Kasaoka T and Taira K: Identification of genes responsible for cell migration by a library of randomized ribozymes. Cancer Res 63: 119-124, 2003.
    • 27. Nakajima M, Hayashi K, Katayama K, Amano Y, Egi Y, Uehata M, Goto N and Kondo T: Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions. Eur J Pharmacol 459: 113-120, 2003.
    • 28. Riento K, Totty N, Villalonga P, Garg R, Guasch R and Ridley AJ: Rho E function is regulated by ROCK I-mediated phosphorylation. EMBO J 24: 1170-1180, 2005.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article